ADXS - Advaxis, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
3.00
-0.08 (-2.60%)
As of 1:58PM EST. Market open.
Stock chart is not supported by your current browser
Previous close3.08
Open3.11
Bid3.02 x 5000
Ask3.03 x 1000
Day's range2.99 - 3.15
52-week range2.83 - 10.06
Volume257,129
Avg. volume875,695
Market cap123.2M
Beta1.72
PE ratio (TTM)N/A
EPS (TTM)-2.29
Earnings date16 Jan 2018 - 20 Jan 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est21.50
Trade prices are not sourced from all markets
  • Business Wire12 days ago

    Advaxis to Present at the Jefferies 2017 London Healthcare Conference

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that company management will participate in the Jefferies 2017 London Healthcare Conference taking place November 15-16, 2017 in London, UK.

  • Business Wire5 months ago

    Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day

    Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, held its annual Investor & Analyst Day this week with clinical investigators and company leaders providing updates and details on the company’s Lm Technology™ and nine development programs. Mark Stein, MD, of Rutgers Cancer Institute of New Jersey, discussed encouraging preliminary immunological data generated from Advaxis’ prostate cancer program with ADXS-PSA in combination with Keytruda® (pembrolizumab). Dr. Stein reported that ADXS-PSA when used as monotherapy was shown to stabilize disease progression in ~30% (4/13) of patients in the dose escalation phase of the study.

  • We're sorry this is all we were able to find about this topic.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes